Published in Mediators Inflamm on February 08, 2010
Gut microbiota and inflammation. Nutrients (2011) 1.60
How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology. J Immunol Res (2015) 0.94
The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol (2011) 0.91
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. Clin Transl Gastroenterol (2012) 0.85
The Interaction among Microbiota, Immunity, and Genetic and Dietary Factors Is the Condicio Sine Qua Non Celiac Disease Can Develop. J Immunol Res (2015) 0.83
Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin. J Immunol Res (2014) 0.77
The Interactions between Innate Immunity and Microbiota in Gastrointestinal Diseases. J Immunol Res (2015) 0.77
Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases. Mediators Inflamm (2014) 0.76
The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. Anal Cell Pathol (Amst) (2015) 0.75
Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease. Nutrients (2016) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 15.27
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature (2008) 14.26
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science (2007) 12.79
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008) 12.67
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity (2009) 9.28
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18
Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol (2000) 9.15
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity (2002) 8.28
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol (2008) 7.91
The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature (2007) 7.82
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol (2007) 6.94
FOXP3: of mice and men. Annu Rev Immunol (2006) 6.89
The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 6.42
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology (1970) 6.06
Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood (2007) 6.03
CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med (2003) 6.00
All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med (2007) 5.96
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A (2006) 5.50
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol (2004) 5.24
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
Control of regulatory T cell lineage commitment and maintenance. Immunity (2009) 4.63
Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol (2001) 4.58
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Developmental regulation of Foxp3 expression during ontogeny. J Exp Med (2005) 4.32
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med (2008) 4.30
A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol (2008) 4.28
Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A (2009) 4.25
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A (2009) 4.10
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 3.95
Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther (2006) 3.93
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology (2007) 3.82
Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A (2002) 3.41
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38
Natural regulatory T cells: mechanisms of suppression. Trends Mol Med (2007) 3.37
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood (2007) 3.33
Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity (2007) 3.33
Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A (2005) 3.33
Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol (2008) 3.03
B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol (2001) 2.99
Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 2.84
A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol (2005) 2.81
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 2.78
Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol (2005) 2.70
Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol (2009) 2.53
Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol (2008) 2.50
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res (2003) 2.45
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer (2003) 2.37
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21
Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol (2009) 2.12
The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun (2008) 2.12
Emerging challenges in regulatory T cell function and biology. Science (2007) 2.11
How do regulatory T cells work? Scand J Immunol (2009) 2.02
CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol (2004) 1.89
Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol (2008) 1.83
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother (2005) 1.80
Th17 cells: from precursors to players in inflammation and infection. Int Immunol (2009) 1.77
The development and function of regulatory T cells. Cell Mol Life Sci (2009) 1.66
Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol (2007) 1.61
Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology (2008) 1.59
IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect (2009) 1.58
CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med (2009) 1.56
Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis (2007) 1.55
Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol (2009) 1.51
Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol (2008) 1.48
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease. Curr Top Microbiol Immunol (2006) 1.45
Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol (2008) 1.44
In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J Exp Med (2006) 1.37
How many mechanisms do regulatory T cells need? Eur J Immunol (2008) 1.34
Human Th17 cells in infection and autoimmunity. Microbes Infect (2009) 1.26
De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J Immunol (2009) 1.26
Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer (2007) 1.26
The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology (2008) 1.23
The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut (2008) 1.23
Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J Immunol (2007) 1.23
All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J Leukoc Biol (2009) 1.23
Therapeutic potential of FOXP3(+) regulatory T cells and their interactions with dendritic cells. Hum Immunol (2009) 1.17
Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology (2008) 1.15
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology (2009) 4.16
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood (2004) 2.64
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol (2005) 2.50
Management of alcohol dependence in patients with liver disease. CNS Drugs (2013) 2.35
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Reflux symptoms in professional opera choristers. Gastroenterology (2007) 2.03
Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol (2011) 1.98
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Unexplained iron deficiency anaemia: Is it worthwhile to perform capsule endoscopy? Dig Liver Dis (2010) 1.68
Lack of endoscopic visualization of intestinal villi with the "immersion technique" in overt atrophic celiac disease. Gastrointest Endosc (2003) 1.64
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
The haematocrit and platelet target in polycythemia vera. Br J Haematol (2006) 1.25
Epstein syndrome: another renal disorder with mutations in the nonmuscle myosin heavy chain 9 gene. Hum Genet (2001) 1.15
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09
Polymyalgia rheumatica in 2011. Best Pract Res Clin Rheumatol (2012) 1.05
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol (2006) 1.02
Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica (2008) 1.01
The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response. Cytokine Growth Factor Rev (2013) 1.01
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Colon capsule endoscopy: Advantages, limitations and expectations. Which novelties? World J Gastrointest Endosc (2012) 1.00
Increased frequency of Ig heavy-chain HS1,2-A enhancer *2 allele in dermatitis herpetiformis, plaque psoriasis, and psoriatic arthritis. J Invest Dermatol (2008) 0.99
Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2002) 0.99
Prophylaxis against venous thromboembolism in patients with cancer. N Engl J Med (2014) 0.97
Management and treatment of lactose malabsorption. World J Gastroenterol (2006) 0.96
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int (2013) 0.95
Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol (2004) 0.94
Ipilimumab Adjuvant Therapy in Melanoma. N Engl J Med (2017) 0.94
Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J (2006) 0.93
Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointest Endosc (2004) 0.93
Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology (2002) 0.92
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf) (2012) 0.92
'Doctor, treat your patient, not your monitor!' Tremor-induced ECG artefacts mimicking torsades de pointes. BMJ Case Rep (2014) 0.91
High prevalence of celiac disease in patients with lactose intolerance. Digestion (2005) 0.91
High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents (2004) 0.91
Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointest Endosc (2004) 0.91
Double-balloon enteroscopy for diagnosis of a Meckel's diverticulum in a patient with GI bleeding of obscure origin. Gastrointest Endosc (2005) 0.91
Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. Hum Immunol (2009) 0.90
Negative capsule endoscopy in patients with obscure gastrointestinal bleeding reliable: recurrence of bleeding on long-term follow-up. World J Gastroenterol (2013) 0.90
Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. Dig Dis (2008) 0.90
HCV infection and extrahepatic manifestations. Hepatogastroenterology (2003) 0.90
IL-1β biological treatment of familial Mediterranean fever. Clin Rev Allergy Immunol (2013) 0.89
Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine (Baltimore) (2014) 0.89
Association of laryngeal cancer with previous gastric resection. Ann Surg (2004) 0.89
Differential diagnosis of pulmonary embolism in outpatients with non-specific cardiopulmonary symptoms. Intern Emerg Med (2011) 0.89
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice. Dig Liver Dis (2013) 0.88
Biliary laryngopharyngeal reflux: a new pathological entity. Curr Opin Otolaryngol Head Neck Surg (2006) 0.88
Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease. Hum Immunol (2008) 0.88
Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative? Int J Vasc Med (2011) 0.87
Moderately severe acute pancreatitis associated with riluzole. J Clin Gastroenterol (2014) 0.87
Celiac disease: what's new about it? Dig Dis (2008) 0.87
Tired legs--a gut diagnosis. Lancet (2010) 0.87
Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol (2010) 0.86
A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol (2010) 0.85
Post-cholecystectomy alkaline reactive gastritis: a randomized trial comparing sucralfate versus rabeprazole or no treatment. Eur J Gastroenterol Hepatol (2003) 0.85
Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler Thromb Vasc Biol (2013) 0.85
The water immersion technique is easy to learn for routine use during EGD for duodenal villous evaluation: a single-center 2-year experience. J Clin Gastroenterol (2009) 0.85
Gastric surgery as a long-term risk factor for malignant lesions of the larynx. Arch Surg (2003) 0.85
Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol (2006) 0.85
Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. Clin Transl Gastroenterol (2012) 0.85
Allele *1 of HS1.2 enhancer associates with selective IgA deficiency and IgM concentration. J Immunol (2009) 0.85
Rapid detection of clarithromycin resistance in Helicobacter pylori using a PCR-based denaturing HPLC assay. J Antimicrob Chemother (2005) 0.84
Involvement of central immunity in uncomplicated diverticular disease. Scand J Gastroenterol (2009) 0.84
Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica (2007) 0.84
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Dig Liver Dis (2012) 0.83
Distinct expression of cyclooxygenase-1 and -2 in the human thymus. Eur J Immunol (2002) 0.83
Autoimmune hemolytic anemia with gel-based immunohematology tests. Am J Clin Pathol (2013) 0.83
Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int J Cardiol (2007) 0.83
Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol (2012) 0.82
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig Dis (2016) 0.81
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease. Mol Biol Rep (2012) 0.81
Obscure recurrent gastrointestinal bleeding: a revealed mystery? Scand J Gastroenterol (2014) 0.81
NSAID enteropathy: could probiotics prevent it? J Gastroenterol (2012) 0.81
Microscopic colitis. World J Gastroenterol (2012) 0.81
IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest (2015) 0.81
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis (2006) 0.81
Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. J Pediatr Gastroenterol Nutr (2004) 0.80
The combined application of advanced endoscopic imaging techniques may increase the duodenal villous morphology definition in suspected celiac disease. Dig Liver Dis (2009) 0.80
High-resolution magnifying upper endoscopy in a patient with patchy celiac disease. Dig Dis Sci (2005) 0.80
[Functional dyspepsia: definition, classification, clinical and therapeutic management]. Ann Ital Med Int (2004) 0.80
Bile acids and total bilirubin detection in saliva of patients submitted to gastric surgery and in particular to subtotal Billroth II resection. Ann Surg (2007) 0.80
Spectral endoscopic imaging: the multiband system for enhancing the endoscopic surface visualization. J Clin Gastroenterol (2011) 0.80
Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban. Thromb Haemost (2003) 0.79
TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes. Acta Diabetol (2014) 0.79